MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Amgen ROCE Ratio 2011-2026 | AMGN
Annual ROCE Ratio Amgen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104.87 | 123.5 | 126.72 | 261.29 | 114.01 | 97.13 | 20.64 | 19.39 | 14.06 | 14.75 | 13.46 | 9.99 | 10.08 | 12.1 | 12.08 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 261.29 | 9.99 | 63.6 |
Quarterly ROCE Ratio Amgen
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 444.96 | 618.67 | 647.61 | 330.81 | 340.85 | 61.79 | 87.86 | 84.99 | 99.64 | 75.79 | 101.39 | 100.91 | 103.91 | 78.84 | 97.42 | 90.41 | 85.38 | 63.05 | 72.71 | 63.79 | 51.82 | 30.62 | 39.08 | 37.87 | 35.15 | 24.47 | 32.79 | 32.66 | 32.09 | 22.92 | 28.61 | 25.97 | 25.95 | 18.36 | 26.0 | 27.95 | 27.58 | 21.18 | 28.65 | 28.47 | 29.79 | 23.55 | 26.31 | 21.6 | 20.27 | 16.55 | 2.76 | 7.0 | 6.79 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 647.61 | 2.76 | 89.87 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.57 | 0.04 % | $ 3.74 B |  USA |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Akebia Therapeutics
AKBA
|
72.06 | $ 1.41 | -1.4 % | $ 363 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 91.98 | -0.11 % | $ 27.2 B | Germany |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.56 | -3.76 % | $ 16.1 M | USA |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.85 | -1.39 % | $ 9.26 B |  Australia |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 20.87 | 2.3 % | $ 976 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.17 | -0.24 % | $ 446 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.57 | -0.16 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
-153.72 | $ 3.17 | 2.59 % | $ 319 M | USA |
 |
Codiak BioSciences
CDAK
|
-129.99 | - | -55.98 % | $ 2.15 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-107.83 | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-115.03 | $ 2.93 | -4.87 % | $ 6.38 B | Israel |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Celldex Therapeutics
CLDX
|
-54.51 | $ 33.62 | 3.73 % | $ 2.23 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
-69.06 | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-60.98 | $ 3.92 | 1.03 % | $ 264 B | Britain |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
-207.46 | - | -6.63 % | $ 13.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |